Singapore, Aug. 14 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
Curie Oncology (Farrer)
National University Hospital
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr John Chia Whay Kuang
Dr David Tan Shao Peng
Dr Valerie Yue Ming Heong
Published by HT Digital Content Services with permission from Health Daily Digest....